Skip to Main Content

A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Conditions

Non-Hodgkin's Lymphoma

Phase I

What is the purpose of this trial?

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

  • Trial with
    Loxo Oncology, Inc.
  • Start Date
    08/12/2021
  • End Date
    10/01/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/16/2021
  • Study HIC
    #2000027406